How changes in soluble tau proteins affect the spread of Alzheimer's disease
Regulation of Pathological Tau Transmission by Soluble Tau Post-Translational Modifications
This study is looking at how certain proteins related to tau might help spread the harmful effects of Alzheimer's disease, with the goal of finding new ways to slow down the disease and help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11065531 on NIH RePORTER |
What this research studies
This research investigates the role of soluble tau proteins and their post-translational modifications in the transmission of pathological tau, which is a key factor in the progression of Alzheimer's disease. The study aims to understand how these modifications can influence the amplification of tau pathology, potentially leading to new therapeutic strategies. By examining the interactions between soluble tau and pathological tau, the researchers hope to uncover mechanisms that could be targeted to slow disease progression. Patients may benefit from insights gained into how tau spreads and how it can be blocked.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies.
Not a fit: Patients with non-tau related neurodegenerative conditions may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown that targeting protein modifications can influence disease progression, suggesting potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Peng, Chao — University of California Los Angeles
- Study coordinator: Peng, Chao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.